{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:30:33Z","timestamp":1767378633556,"version":"3.48.0"},"reference-count":14,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Background<\/jats:title>\n The impact of single-dose preoperative evolocumab combined with rosuvastatin therapy prior to emergency percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction (STEMI) remains insufficiently characterized within current guideline-directed medical therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this prospective randomized trial conducted at Liaocheng People\u2019s Hospital (2023\u20132024), 80 STEMI patients undergoing emergency PCI were randomized to: Treatment group: Single subcutaneous evolocumab 140\u2009mg plus oral rosuvastatin 10\u2009mg administered pre-PCI, followed by rosuvastatin 10\u2009mg\/day; Control group: Rosuvastatin 10\u2009mg\/day alone initiated post-PCI. Primary endpoint was major adverse cardiovascular events (MACEs) at 6 months. Secondary endpoints included angina incidence, low-density lipoprotein cholesterol (LDL-C) levels, interleukins, and ST-segment resolution rate (STR). The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2500099498).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Primary endpoint (MACEs): 5.0% (treatment group) vs. 12.5% (control group)(P\u2009=\u20090.228) at 6-month follow-up. Secondary endpoints: Angina incidence: 7.5% vs 27.5% (P\u2009=\u20090.037) at 6-month follow-up; LDL-C reduction: Significant in treatment group at day 1 (2.97\u2009\u00b1\u20090.63 vs 3.33\u2009\u00b1\u20090.78 mmol\/L; P\u2009=\u20090.029), day 7 (1.66\u2009\u00b1\u20090.89 vs 2.25\u2009\u00b1\u20090.77 mmol\/L, P\u2009=\u20090.003), and month 1 (P\u2009=\u20090.036); ST-segment resolution >70%: 60% vs 30% (P\u2009<\u20090.05); Inflammatory markers: Lower IL-6 (P\u2009=\u20090.02) and IL-17 (P\u2009=\u20090.01) in treatment group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n While the evolocumab-rosuvastatin combination did not significantly reduce 6-month MACEs, it demonstrated clinically important benefits including reduced angina frequency, accelerated LDL-C lowering, improved myocardial reperfusion, and attenuated inflammatory response, with a favorable safety profile. These findings support further investigation of intensive lipid-lowering strategies in acute STEMI management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0339501","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:26:22Z","timestamp":1767378382000},"page":"e0339501","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of preoperative evolocumab-rosuvastatin combination therapy in patients with ST-elevation myocardial infarction"],"prefix":"10.1371","volume":"21","author":[{"given":"Hongxu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0110-4620","authenticated-orcid":true,"given":"Zuolin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"43","key":"pone.0339501.ref001","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035687","article-title":"Comprehensive review of ST-segment elevation myocardial infarction: Understanding pathophysiology, diagnostic strategies, and current treatment approaches","volume":"102","author":"C Elendu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pone.0339501.ref002","first-page":"92","article-title":"Depression, Anxiety, and Quality of Life in a Cardiac Rehabilitation Program Without Dedicated Mental Health Resources Post-Myocardial Infarction","volume":"12","author":"C Bertol\u00edn-Boronat","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"issue":"9","key":"pone.0339501.ref003","first-page":"949","article-title":"Report on cardiovascular health and diseases in china 2023: an updated summary","volume":"37","author":"Center For Cardiovascular Diseases The Writing Committee Of The Report On Cardiovascular Health And Diseases In China N","year":"2024","journal-title":"Biomed Environ Sci"},{"issue":"9493","key":"pone.0339501.ref004","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"C Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"pone.0339501.ref005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"2023 China guidelines for lipid management","volume":"20","author":"J-J Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"issue":"9","key":"pone.0339501.ref006","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5551\/jat.55400","article-title":"An update on the role of PCSK9 in Atherosclerosis","volume":"27","author":"E Yurtseven","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"pone.0339501.ref007","doi-asserted-by":"crossref","first-page":"117180","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque","volume":"378","author":"R Marfella","year":"2023","journal-title":"Atherosclerosis"},{"issue":"3","key":"pone.0339501.ref008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"CP Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"pone.0339501.ref009","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"MS Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0339501.ref010","first-page":"766","article-title":"2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction","volume":"47","author":"Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology","year":"2019","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"11","key":"pone.0339501.ref011","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial","volume":"18","author":"SR Mehta","year":"2022","journal-title":"EuroIntervention"},{"issue":"1","key":"pone.0339501.ref012","first-page":"55","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"13","author":"RA Byrne","year":"2023","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"key":"pone.0339501.ref013","doi-asserted-by":"crossref","first-page":"111195","DOI":"10.1016\/j.intimp.2023.111195","article-title":"PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB\/CD44 pathway","volume":"126","author":"Y Zheng","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"pone.0339501.ref014","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","article-title":"Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"O De Filippo","year":"2023","journal-title":"Cardiovasc Diabetol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:26:25Z","timestamp":1767378385000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339501"}},"subtitle":[],"editor":[{"given":"Kamal","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339501","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}